Tenaya Therapeutics (TNYA) Cash from Operations (2020 - 2026)
Tenaya Therapeutics' quarterly Cash from Operations came in at 19234000.0 in Q1 2026, up 16.78% year-on-year from 16470404.15 in Q1 2025, and down 37.98% quarter-over-quarter from 13940000.0 in Q4 2025.
Tenaya Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 19234000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 16.78% year-over-year to 19234000.0; the trailing twelve-month figure through Mar 2026 stood at 64386000.0 (up 24.21% YoY), and the FY2025 full-year result was 68264000.0, up 24.57% from the prior year.
- Cash from Operations for Q1 2026 stood at 19234000.0, down from 13940000.0 in the prior quarter.
- The five-year high for Cash from Operations was 13940000.0 in Q4 2025, with the low at 30290000.0 in Q1 2023.
- Average Cash from Operations over 5 years is 22617352.94, with a median of 23112000.0 recorded in 2025.
- Year-over-year, Cash from Operations tumbled 111.58% in 2022 and soared 33.89% in 2025.
- Tracing TNYA's Cash from Operations over 5 years: stood at 22682000.0 in 2022, then advanced by 3.34% to 21924000.0 in 2023, then gained by 16.13% to 18388000.0 in 2024, then gained by 24.19% to 13940000.0 in 2025, then sank by 37.98% to 19234000.0 in 2026.
- The last three Cash from Operations figures came in at 19234000.0 (Q1 2026), 13940000.0 (Q4 2025), and 15599000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - | -19.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.23 Mn |
| Mar 31, 2026 | -19.23 Mn |
| Dec 31, 2025 | -13.94 Mn |
| Dec 31, 2025 | -13.94 Mn |
| Sep 30, 2025 | -15.60 Mn |
| Sep 30, 2025 | -15.60 Mn |
| Jun 30, 2025 | -15.61 Mn |
| Jun 30, 2025 | -15.61 Mn |
| Mar 31, 2025 | -23.11 Mn |
| Mar 31, 2025 | -23.11 Mn |
| Dec 31, 2024 | -18.39 Mn |
| Dec 31, 2024 | -18.39 Mn |
| Sep 30, 2024 | -19.84 Mn |
| Sep 30, 2024 | -19.84 Mn |
| Jun 30, 2024 | -23.62 Mn |
| Jun 30, 2024 | -23.62 Mn |
| Mar 31, 2024 | -28.66 Mn |
| Mar 31, 2024 | -28.66 Mn |
| Dec 31, 2023 | -21.92 Mn |
| Dec 31, 2023 | -21.92 Mn |
| Sep 30, 2023 | -23.64 Mn |
| Sep 30, 2023 | -23.64 Mn |
| Jun 30, 2023 | -26.22 Mn |
| Jun 30, 2023 | -26.22 Mn |
| Mar 31, 2023 | -30.29 Mn |
| Mar 31, 2023 | -30.29 Mn |
| Dec 31, 2022 | -22.68 Mn |
| Dec 31, 2022 | -22.68 Mn |
| Sep 30, 2022 | -27.56 Mn |
| Sep 30, 2022 | -27.56 Mn |
| Jun 30, 2022 | -25.43 Mn |
| Jun 30, 2022 | -25.43 Mn |
| Mar 31, 2022 | -28.76 Mn |
| Mar 31, 2022 | -28.76 Mn |
| Dec 31, 2021 | -16.35 Mn |
| Dec 31, 2021 | -16.35 Mn |
| Sep 30, 2021 | -16.66 Mn |
| Sep 30, 2021 | -16.66 Mn |
| Jun 30, 2021 | -12.02 Mn |
| Jun 30, 2021 | -12.02 Mn |
| Mar 31, 2021 | -15.79 Mn |
| Mar 31, 2021 | -15.79 Mn |
| Dec 31, 2020 | -10.40 Mn |
| Dec 31, 2020 | -10.40 Mn |
| Sep 30, 2020 | -9.53 Mn |
| Sep 30, 2020 | -9.53 Mn |